ClinicalTrials.gg
CompletedNCT03516981Updated Jun 8, 2026Results posted

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

A Phase 2 interventional study of Pembrolizumab and Favezelimab in Advanced Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 81 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.

Read the detailed description

After Amendment 5, participants can receive 800 mg of favezelimab every 3 weeks (Q3W)

02

Conditions studied

  • Advanced Non-Small Cell Lung Cancer

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a - or cytologically-confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for advanced disease
  • Has confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly accelerated fibrosarcoma- (B-Raf-) directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR mutations, B-Raf mutations, ALK gene rearrangements, and ROS1 gene rearrangements)
  • Has per 1.1 as assessed by the local site investigator/radiology
  • Male participants must agree to use during the treatment period and for ≥120 days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condom
  • Female participants eligible to participate if not pregnant, not breastfeeding, and not a woman of (WOCBP) or is a WOCBP who agrees to follow contraceptive guidance during the treatment period and for ≥120 days after the last dose of study treatment
  • Provided sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Has an (ECOG) performance status of 0 to 1
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has significant cardiovascular impairment within 12 months of the first dose of study drug: history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA) stroke, or cardiac arrhythmia associated with hemodynamic instability, significant cardiovascular impairment, or a (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram
  • Prolongation of to >480 milliseconds (ms)
  • Has symptomatic ascites or pleural effusion
  • Has had an allogenic tissue/solid organ transplant
  • who has a positive urine pregnancy test within 24 hours before the first dose of study treatment
  • Has not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy, or has had major surgery within 3 weeks prior to first dose of study intervention
  • Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula, gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
  • Radiographic evidence of major blood vessel invasion/infiltration
  • hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
  • Has received prior systemic chemotherapy treatment for /recurrent NSCLC
  • Has current NSCLC disease that can be treated with curative intent with surgical resection, localized radiotherapy, or chemoradiation
  • Is expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC, radiation therapy, and/or surgical resection)
  • Has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor
  • Has received previous treatment with another agent targeting the Lymphocyte-activation gene 3 (LAG-3) receptor
  • Has received previous treatment with another agent targeting vascular endothelial growth factor (VEGF) or the VEGF receptor
  • Has received prior anticancer therapy including agents within 4 weeks prior to randomization
  • Has received prior radiotherapy within 2 weeks of start of study treatment or received lung radiation therapy of >30 Gy within 6 months prior to the first dose of study intervention
  • Has received a live or within 30 days before the first dose of study treatment
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has severe (≥Grade 3) to pembrolizumab, favezelimab, or lenvatinib and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)
  • Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days (females and males) after the last dose of study treatment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib

    Participants received pembrolizumab 200 mg every 3 weeks (Q3W) intravenously (IV) plus lenvatinib 20 mg orally once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Experimental
    Pembrolizumab + Quavonlimab

    Participants received pembrolizumab 200 mg Q3W IV plus quavonlimab 25 mg every 6 weeks (Q6W) IV until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).

    Biological: Pembrolizumab · Drug: Quavonlimab

  • Experimental
    Pembrolizumab + Favezelimab 200 mg

    Participants received pembrolizumab 200 mg Q3W IV plus favezelimab 200 mg Q3W IV until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).

    Biological: Pembrolizumab · Biological: Favezelimab

  • Experimental
    Pembrolizumab + Favezelimab 800 mg

    Participants received pembrolizumab 200 mg Q3W IV plus favezelimab 800 mg Q3W IV until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).

    Biological: Pembrolizumab · Biological: Favezelimab

Interventions

  • BiologicalPembrolizumab

    200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

    Also known as: MK-3475

  • BiologicalFavezelimab

    200 mg or 800 mg favezelimab solution for IV infusion administered Q3W

    Also known as: MK-4280

  • 20 mg lenvatinib capsules administered orally once daily

    Also known as: MK-7902

  • Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)

    Also known as: MK-1308

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by local site radiologic review. The percentage of participants who experience CR or PR as assessed by local site radiologic review with confirmatory assessment per RECIST 1.1 is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.

    Time frame: Up to approximately 80 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from allocation to the first documented progressive disease (PD) or death due to any cause, whichever occurs first according to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by local site radiologic review. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.

    Time frame: Up to approximately 80 months

  2. Overall Survival (OS)

    OS was defined as the time from the date of allocation to death due to any cause. The OS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.

    Time frame: Up to approximately 80 months

  3. Number of Participants Experiencing Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm experiencing an AE is reported.

    Time frame: Up to approximately 80 months

  4. Number of Participants Discontinuing Study Drug Due to AEs

    An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm that discontinued study drug due to an AE is reported.

    Time frame: Up to approximately 39 months

07

Results

Posted Jun 8, 2026

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mg
Started81833051
Treated80823051
Completed0000
Not completed81833051
Withdrew: Withdrawal by subject2503
Withdrew: Sponsor decision916512
Withdrew: Randomized by mistake without study treatment1100
Withdrew: Lost to follow-up0002
Withdrew: Death69612534

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by local site radiologic review. The percentage of participants who experience CR or PR as assessed by local site radiologic review with confirmatory assessment per RECIST 1.1 is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.

Time frame:
Up to approximately 80 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsPembrolizumab + Lenvatinib - GEP Low / TMB LowPembrolizumab + Lenvatinib - GEP Low / TMB HighPembrolizumab + Lenvatinib - GEP High / TMB LowPembrolizumab + Lenvatinib - GEP High / TMB HighPembrolizumab + Quavonlimab - GEP Low / TMB LowPembrolizumab + Quavonlimab - GEP Low / TMB HighPembrolizumab + Quavonlimab - GEP High / TMB LowPembrolizumab + Quavonlimab - GEP High / TMB HighPembrolizumab + Favezelimab 200 mg - GEP Low / TMB LowPembrolizumab + Favezelimab 200 mg - GEP Low / TMB HighPembrolizumab + Favezelimab 200 mg - GEP High / TMB LowPembrolizumab + Favezelimab 200 mg - GEP High / TMB HighPembrolizumab + Favezelimab 800 mg - GEP Low / TMB HighPembrolizumab + Favezelimab 800 mg - GEP High / TMB LowPembrolizumab + Favezelimab 800 mg - GEP High / TMB High
Objective Response Rate (ORR)12.0 (2.5 to 31.2)33.3 (9.9 to 65.1)40.9 (20.7 to 63.6)57.1 (34.0 to 78.2)11.5 (2.4 to 30.2)30.8 (9.1 to 61.4)13.6 (2.9 to 34.9)52.4 (29.8 to 74.3)0.0 (0.0 to 28.5)33.3 (4.3 to 77.7)25.0 (3.2 to 65.1)60.0 (14.7 to 94.7)27.3 (6.0 to 61.0)13.6 (2.9 to 34.9)50.0 (26.0 to 74.0)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from allocation to the first documented progressive disease (PD) or death due to any cause, whichever occurs first according to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by local site radiologic review. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.

Time frame:
Up to approximately 80 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsPembrolizumab + Lenvatinib - GEP Low / TMB LowPembrolizumab + Lenvatinib - GEP Low / TMB HighPembrolizumab + Lenvatinib - GEP High / TMB LowPembrolizumab + Lenvatinib - GEP High / TMB HighPembrolizumab + Quavonlimab - GEP Low / TMB LowPembrolizumab + Quavonlimab - GEP Low / TMB HighPembrolizumab + Quavonlimab - GEP High / TMB LowPembrolizumab + Quavonlimab - GEP High / TMB HighPembrolizumab + Favezelimab 200 mg - GEP Low / TMB LowPembrolizumab + Favezelimab 200 mg - GEP Low / TMB HighPembrolizumab + Favezelimab 200 mg - GEP High / TMB LowPembrolizumab + Favezelimab 200 mg - GEP High / TMB HighPembrolizumab + Favezelimab 800 mg - GEP Low / TMB HighPembrolizumab + Favezelimab 800 mg - GEP High / TMB LowPembrolizumab + Favezelimab 800 mg - GEP High / TMB High
Progression Free Survival (PFS)5.4 (2.3 to 8.8)13.8 (1.5 to 19.4)8.2 (4.2 to 19.7)17.8 (6.0 to 20.7)2.8 (2.0 to 6.0)3.9 (1.9 to 17.3)6.1 (2.1 to 12.8)17.0 (9.3 to 29.1)2.1 (1.9 to 2.1)8.1 (1.7 to NA)2.1 (0.9 to 6.5)6.3 (0.4 to NA)4.2 (1.8 to 12.2)3.5 (2.0 to 8.2)20.2 (6.1 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of allocation to death due to any cause. The OS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.

Time frame:
Up to approximately 80 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + Lenvatinib - GEP Low / TMB LowPembrolizumab + Lenvatinib - GEP Low / TMB HighPembrolizumab + Lenvatinib - GEP High / TMB LowPembrolizumab + Lenvatinib - GEP High / TMB HighPembrolizumab + Quavonlimab - GEP Low / TMB LowPembrolizumab + Quavonlimab - GEP Low / TMB HighPembrolizumab + Quavonlimab - GEP High / TMB LowPembrolizumab + Quavonlimab - GEP High / TMB HighPembrolizumab + Favezelimab 200 mg - GEP Low / TMB LowPembrolizumab + Favezelimab 200 mg - GEP Low / TMB HighPembrolizumab + Favezelimab 200 mg - GEP High / TMB LowPembrolizumab + Favezelimab 200 mg - GEP High / TMB HighPembrolizumab + Favezelimab 800 mg - GEP Low / TMB HighPembrolizumab + Favezelimab 800 mg - GEP High / TMB LowPembrolizumab + Favezelimab 800 mg - GEP High / TMB High
Overall Survival (OS)16.0 (5.4 to 20.2)16.9 (3.8 to 33.2)22.5 (12.0 to 41.3)22.7 (16.9 to 56.0)13.3 (8.4 to 20.0)20.1 (7.7 to NA)23.7 (7.9 to 43.1)51.6 (17.6 to NA)8.6 (3.8 to 35.4)20.8 (1.7 to NA)12.6 (0.9 to 25.4)NA (13.5 to NA)18.6 (3.4 to 41.2)11.1 (5.2 to 19.6)NA (13.0 to NA)
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm experiencing an AE is reported.

Time frame:
Up to approximately 80 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsPembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mg
Number of Participants Experiencing Adverse Events (AEs)79782749
SecondaryNumber of Participants Discontinuing Study Drug Due to AEs

An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm that discontinued study drug due to an AE is reported.

Time frame:
Up to approximately 39 months
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to AEs
ParticipantsPembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mg
Number of Participants Discontinuing Study Drug Due to AEs3418415

Adverse events

Collected over Up to approximately 80 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Lenvatinib71/81 (87.7%)42/80 (52.5%)76/80 (95%)
Pembrolizumab + Quavonlimab63/83 (75.9%)39/82 (47.6%)75/82 (91.5%)
Pembrolizumab + Favezelimab 200 mg25/30 (83.3%)14/30 (46.7%)25/30 (83.3%)
Pembrolizumab + Favezelimab 800 mg36/51 (70.6%)31/51 (60.8%)47/51 (92.2%)
Most frequent serious events
Showing 10 of 137
Most frequent serious events
EventPembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mg
PneumoniaInfections and infestations6/806/822/304/51
Ischaemic strokeNervous system disorders0/800/822/300/51
Myocardial infarctionCardiac disorders5/800/820/300/51
Pericardial effusionCardiac disorders0/800/820/303/51
COVID-19Infections and infestations0/803/820/303/51
Pleural effusionRespiratory, thoracic and mediastinal disorders1/803/821/303/51
PneumonitisRespiratory, thoracic and mediastinal disorders1/802/820/303/51
COVID-19 pneumoniaInfections and infestations3/801/820/302/51
HyponatraemiaMetabolism and nutrition disorders1/801/821/302/51
DiarrhoeaGastrointestinal disorders3/801/821/301/51
Most frequent other events
Showing 10 of 70
Most frequent other events
EventPembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mg
HypertensionVascular disorders42/804/821/303/51
DiarrhoeaGastrointestinal disorders36/8016/823/3015/51
HypothyroidismEndocrine disorders29/807/824/3010/51
Decreased appetiteMetabolism and nutrition disorders27/8015/826/307/51
AstheniaGeneral disorders26/8011/824/306/51
FatigueGeneral disorders26/8017/821/3011/51
PruritusSkin and subcutaneous tissue disorders12/8024/826/309/51
ConstipationGastrointestinal disorders23/809/826/306/51
NauseaGastrointestinal disorders22/8013/824/308/51
StomatitisGastrointestinal disorders22/805/820/301/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mgTotal
Mean65.4 ± 9.467.3 ± 9.762.4 ± 10.167.9 ± 8.466.2 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mgTotal
Female313091585
Male50532136160
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mgTotal
Hispanic or Latino22307
Not Hispanic or Latino76792748230
Unknown or Not Reported32038
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mgTotal
American Indian or Alaska Native01001
Asian222581974
Native Hawaiian or Other Pacific Islander00000
Black or African American13004
White56522131160
More than one race00000
Unknown or Not Reported22116
Biomarker Defined Subgroups
Biomarker Defined Subgroups(Participants)Pembrolizumab + LenvatinibPembrolizumab + QuavonlimabPembrolizumab + Favezelimab 200 mgPembrolizumab + Favezelimab 800 mgTotal
GEP Low / TMB Low252611062
GEP Low / TMB High131361143
GEP High / TMB Low222282274
GEP High / TMB High212251866
08

Study locations

81 sites
  • Arizona Oncology Associates, PC- HAL ( Site 8001)
    Tempe, Arizona 85284, United States
  • University of California Davis Comprehensive Cancer Center ( Site 0137)
    Sacramento, California 95817, United States
  • University of California San Francisco ( Site 0111)
    San Francisco, California 94143, United States
  • UCLA Hematology/Oncology -Santa Monica ( Site 0108)
    Santa Monica, California 90404, United States
  • Yale University School of Medicine ( Site 0100)
    New Haven, Connecticut 06520, United States
  • Mayo Clinic Florida ( Site 0115)
    Jacksonville, Florida 32224, United States
  • University of Maryland ( Site 0136)
    Baltimore, Maryland 21201, United States
  • Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117)
    Rochester, Minnesota 55905, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0112)
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0113)
    New York, New York 10065, United States
  • Weill Cornell Medical College ( Site 0138)
    New York, New York 10065, United States
  • Oncology Hematology Care ( Site 8005)
    Cincinnati, Ohio 45242, United States
  • University of Pennsylvania ( Site 0132)
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Cancer Center/Hillman Cancer Center ( Site 0104)
    Pittsburgh, Pennsylvania 15232, United States
  • Texas Oncology-Memorial City ( Site 8006)
    Houston, Texas 77024, United States
  • Texas Oncology-Tyler ( Site 8003)
    Tyler, Texas 75702, United States
  • Emily Couric Clinical Cancer Center ( Site 0134)
    Charlottesville, Virginia 22903, United States
  • Northwest Cancer Specialists, P.C. ( Site 8000)
    Vancouver, Washington 98684, United States
  • University of Wisconsin- Madison Carbone Cancer Center ( Site 0130)
    Madison, Wisconsin 53792, United States
  • Blacktown Hospital Western Sydney Local Health District ( Site 0200)
    Blacktown, New South Wales 2148, Australia
  • Gallipoli Medical Research Foundation ( Site 0202)
    Brisbane, Queensland 4120, Australia
  • Fiona Stanley Hospital ( Site 0201)
    Murdoch, Western Australia 6150, Australia
  • The Ottawa Hospital ( Site 0306)
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Science Centre ( Site 0304)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0309)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS du Saguenay-Lac-St-Jean ( Site 0305)
    Chicoutimi, Quebec G7H 5H6, Canada
  • Jewish General Hospital ( Site 0307)
    Montreal, Quebec H3T 1E2, Canada
  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0310)
    Montreal, Quebec H3T 1M5, Canada
  • Prince of Wales Hospital ( Site 1801)
    Hong Kong, 000, Hong Kong
  • Queen Mary Hospital ( Site 1800)
    Hong Kong, Hong Kong
  • St James Hospital ( Site 2200)
    Dublin, D08 K0Y5, Ireland
  • Mid Western Cancer Centre ( Site 2201)
    Limerick, V94 YVH0, Ireland
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702)
    Meldola, Emilia-Romagna 47014, Italy
  • Istituto Clinico Humanitas Research Hospital ( Site 0700)
    Rozzano, Lombardy 20089, Italy
  • AOU San Luigi Gonzaga di Orbassano ( Site 0707)
    Orbassano, Torino 10043, Italy
  • AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701)
    Legnago, Verona 37045, Italy
  • Azienda Ospedaliera Papardo ( Site 0706)
    Messina, 98158, Italy
  • Seconda Universita degli Studi di Napoli ( Site 0704)
    Naples, 80131, Italy
  • Fondazione Policlinico Universitario A. Gemelli ( Site 0703)
    Roma, 00168, Italy
  • Azienda Ospedaliera Universitaria Senese ( Site 0705)
    Siena, 53100, Italy
  • National Cancer Center Hospital ( Site 2001)
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of JFCR ( Site 2000)
    Tokyo, 135-8550, Japan
  • MED-POLONIA Sp. z o.o. ( Site 0907)
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Dolnoslaskie Centrum Onkologii. ( Site 0993)
    Wroclaw, Lower Silesian Voivodeship 53-413, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1003)
    Ufa, Baskortostan, Respublika 450054, Russia
  • The Loginov Moscow Clinical Scientific Center ( Site 1008)
    Moscow, Moscow 111123, Russia
  • N.N. Blokhin NMRCO ( Site 1000)
    Moscow, Moscow 115478, Russia
  • Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site
    Omsk, Omsk Oblast 644013, Russia
  • SBHI Leningrad Regional Clinical Hospital ( Site 1001)
    Saint Petersburg, Sankt-Peterburg 194291, Russia
  • St Petersburg City Clinical Oncology Dispensary ( Site 1002)
    Saint Petersburg, Sankt-Peterburg 198255, Russia
  • Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1005)
    Kazan', Tatarstan, Respublika 420029, Russia
  • National Cancer Centre Singapore ( Site 1900)
    Singapore, Central Singapore 169610, Singapore
  • National University Hospital ( Site 1901)
    Singapore, South West 119074, Singapore
  • MPOC ( Site 2310)
    Groenkloof Pretoria, Gauteng 0181, South Africa
  • Wits Clinical Research ( Site 2313)
    Parktown-Johannesburg, Gauteng 2193, South Africa
  • Univ. Pretoria and Steve Biko Academic Hospitals ( Site 2315)
    Pretoria, Gauteng 0002, South Africa
  • Sandton Oncology Medical Group PTY LTD ( Site 2316)
    Sandton, Gauteng 2196, South Africa
  • Vaal Triangle Oncology Centre ( Site 2314)
    Vereeniging, Gauteng 1939, South Africa
  • Umhlanga Oncolgy Center ( Site 2311)
    Umhlanga, KwaZulu-Natal 4320, South Africa
  • Cape Town Oncology Trials Pty Ltd ( Site 2312)
    Kraaifontein, Western Cape 7570, South Africa
  • Seoul National University Bundang Hospital ( Site 0803)
    Seongnam-si, Kyonggi-do 13620, South Korea
  • Asan Medical Center ( Site 0801)
    Songpa-gu, Seoul 05505, South Korea
  • Seoul National University Hospital ( Site 0800)
    Seoul, 03080, South Korea
  • Severance Hospital Yonsei University Health System ( Site 0802)
    Seoul, 03722, South Korea
  • Samsung Medical Center ( Site 0805)
    Seoul, 06351, South Korea
  • Hospital General Universitari Vall d Hebron ( Site 1100)
    Barcelona, 08035, Spain
  • Hospital Universitario Ramon y Cajal ( Site 1101)
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre ( Site 1102)
    Madrid, 28041, Spain
  • Kantonsspital St. Gallen ( Site 2102)
    Saint Gallen, Canton of Aargau 9007, Switzerland
  • Universitaetsspital Basel ( Site 2104)
    Basel, Canton of Basel-City 4031, Switzerland
  • Hopitaux Universitaires de Geneve HUG ( Site 2106)
    Geneva, Canton of Geneva 1211, Switzerland
  • Universitaetsspital Zuerich ( Site 2100)
    Zurich, Canton of Zurich 8091, Switzerland
  • Kantonsspital Graubuenden ( Site 2103)
    Chur, Kanton Graubünden 7000, Switzerland
  • Kaohsiung Chang Gung Memorial Hospital ( Site 1203)
    Kaohsiung City, 83301, Taiwan
  • National Cheng Kung University Hospital ( Site 1202)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 1200)
    Taipei, 10048, Taiwan
  • Taipei Veterans General Hospital ( Site 1204)
    Taipei, 11217, Taiwan
  • Cambridge University Hospitals NHS Trust ( Site 1306)
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • University College London Hospital NHS Foundation Trust ( Site 1308)
    London, London, City of NW1 2PG, United Kingdom
  • Derriford Hospital ( Site 1301)
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Publications

  • Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nat Med. 2023 Jul;29(7):1718-1727. doi: 10.1038/s41591-023-02385-6. Epub 2023 Jul 10. PubMed 37429923 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jun 2025, 80 months.

Results were first posted in Jun 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2018
First posted
May 7, 2018
StartActual
Oct 1, 2018
Primary completionActual
Jun 13, 2025
CompletionActual
Jun 13, 2025
Results first posted
Jun 8, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03516981
Responsible party
Sponsor
First posted
May 7, 2018
Start date
Oct 1, 2018
Primary completion
Jun 13, 2025
Completion
Jun 13, 2025
Results posted
Jun 8, 2026
Last update
Jun 8, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Favezelimab · Lenvatinib · Quavonlimab

Start the discussion